Overview

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

Status:
Completed

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

The HIV integrase inhibitor, raltegravir (RAL), which was recently approved by the FDA, has been shown in several trials to be highly effective. The purpose of this trial is to estimate the viral load decay rate in treatment-naive HIV infected participants receiving RAL and emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).

Phase:

Phase 1

Details

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator:

Adult AIDS Clinical Trials Group

Treatments:

Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Raltegravir Potassium
Tenofovir